Namir Hassan

Namir Hassan

Company: Zelluna Immunotherapy

Job title: Chief Executive Officer


TCR-NK: A Novel Treatment Paradigm For The Treatment of Solid Cancer 10:45 am

TCR-NK is a novel treatment paradigm that brings together the well validated solid tumour targeting mechanism of T-Cell Receptors (TCRs) with the pan cancer recognition and highly potent activity of Natural Killer Cells (NKs) We show the polyfunctionality of TCR-NKs triggered by both the high specificity of TCRs as well as pan cancer innate NK…Read more

day: Day 2 - Track A - Morning

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.